GlassScriptPhysician profile
Nicholas G Conger
NPI 1598743890
$75,977.52
in general payments reported to CMS, 2019-2025
36 companies · $45K in 2025
The $45K reported for 2025 was more than what 98% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,131 · 2020: $857 · 2021: $1,421 · 2022: $1,809 · 2023: $2,144 · 2024: $23K · 2025: $45K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $56K · Food and Beverage: $7,956 · Travel and Lodging: $6,402 · Education: $177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $56,225.00 |
| Food and Beverage | $7,956.39 |
| Travel and Lodging | $6,401.88 |
| Education | $176.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $67,227.41 | 2019-2025 | Cabenuva, Dovato, Apretude |
| Gilead Sciences, INC. | $1,759.09 | 2019-2025 | Biktarvy, Veklury |
| Astellas Pharma US INC | $1,138.47 | 2019-2025 | Cresemba |
| Insmed, INC. | $1,073.46 | 2019-2025 | Arikayce, Brinsupri |
| Merck Sharp & Dohme LLC | $1,061.69 | 2019-2025 | Zerbaxa, Dificid, Pifeltro |
| Melinta Therapeutics, LLC | $812.19 | 2019-2025 | Kimyrsa, Rezzayo, Vabomere |
| Paratek Pharmaceuticals, INC. | $620.69 | 2019-2024 | Nuzyra |
| Abbvie INC. | $368.37 | 2019-2025 | Mavyret |
| Shionogi INC | $303.92 | 2021-2025 | Fetroja |
| Accelerate Diagnostics INC. | $263.08 | 2019-2022 | |
| Dynavax Technologies Corporation | $183.20 | 2019 | |
| Theratechnologies INC. | $171.14 | 2021-2025 | Egrifta, Trogarzo |
| Janssen Biotech, INC. | $119.16 | 2020-2024 | Symtuza, Stelara |
| La Jolla Pharmaceutical Company | $115.23 | 2021-2025 | Zevtera, Xerava |
| Cumberland Pharmaceuticals, INC. | $102.94 | 2019-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $102.06 | 2020-2023 | Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.84 | 2019-2022 | |
| Daiichi Sankyo INC. | $50.83 | 2019 | |
| Aimmune Therapeutics, INC. | $41.94 | 2025 | Vowst |
| Invivyd INC | $38.82 | 2024-2025 | Pemgarda |
| Emd Serono, INC. | $36.26 | 2019 | |
| Pharmacosmos Therapeutics INC. | $36.08 | 2022 | |
| Alnylam Pharmaceuticals INC. | $34.79 | 2022-2023 | Givlaari |
| Allergan, INC. | $27.93 | 2020 | |
| Tetraphase Pharmaceuticals, INC. | $27.08 | 2019 | |
| Pfizer INC. | $25.47 | 2021 | |
| Mayne Pharma Commercial LLC | $22.52 | 2022 | |
| Qiagen, LLC | $19.99 | 2022 | |
| Vyera Pharmaceuticals, LLC | $19.31 | 2020 | |
| Ucb, INC. | $18.14 | 2019 | |
| Organogenesis INC. | $17.43 | 2025 | Puraply Wound Matrix |
| Intercept Pharmaceuticals, INC. | $16.97 | 2022 | |
| Seqirus USA INC | $16.92 | 2019 | |
| Biomerieux INC | $13.52 | 2025 | Filmarray Meningitis/Encephalitis (Me) Panel |
| Ferring Pharmaceuticals INC. | $13.48 | 2023 | Rebyota |
| Advanced Oxygen Therapy INC. | $8.10 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Conger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.